Skip to main content
NACFC 2026 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Recorded Session
Recorded Session
Livestreamed Session
Livestreamed Session
Session is Ticketed (Add-on Session through Registration)
Session is Ticketed (Add-on Session through Registration)
Food Available for Session Attendees
Food Available for Session Attendees
Session includes an in person invitee/speaker with CF
Session includes an in person invitee/speaker with CF

Workshop

CLIN

W14-- Epidemiology of CF New Patterns & Outcomes

Thursday, October 8, 2026
10:15 AM - 12:15 PM EDT
This workshop will highlight emerging real-world evidence from national and international CF registries examining how ETI is influencing treatment practices, disease trajectories, and long-term outcomes across diverse patient populations. Presentations will explore the impact of ETI on inhaled antibiotic use, lung function trajectories in children, airway microbiology, biomarker-based outcomes, and evolving life-course issues such as parenthood. Through these studies, participants will gain insight into how epidemiologic methods and registry data can be used to understand changing patterns of care and outcomes in the post-modulator era.

Presentation Order:



1. Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor (ETI) on Long-Term Lung Function Trajectory Among Children Ages 6–17 in the United States – Presented by Margaret Rosenfeld

2. Association Between CFTR-Modulated Sweat Chloride Concentrations and Clinical Outcomes Across the CF Population: Top-Line Results From the CHEC-SC Study – Presented by Nicole Mayer-Hamblett

3. Clinical Outcomes Following Inhaled Antibiotic Discontinuation in People with CF Treated with Elexacaftor/Tezacaftor/Ivacaftor (ETI): Real-World Evidence from the European CF Patient Registry – Presented by Damian Downey

4. The Impact of Parenthood and Elexacaftor/Tezacaftor/Ivacaftor Use on Lung Function Trajectories: Evidence from the UK Cystic Fibrosis Registry, 2016–2024 – Presented by Meijie Chu

5. Long-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor on Airway Microbiology and Clinical Outcomes in Cystic Fibrosis: A Target Trial Emulation Study – Presented by Ze Chen